Nanotherapy in Joints: Increasing Endogenous Hyaluronan Production by Delivering Hyaluronan Synthase 2.
Osteoarthritis (OA) is a common joint degenerative disease that causes pain, joint damage, and dysfunction. External hyaluronic acid (HA) supplement is a common method for the management of osteoarthritis which requires multi-injections. It is demonstrated that biodegradable mesoporous silica nanoparticles successfully deliver an enzyme, hyaluronan synthase type 2 (HAS2), into synoviocytes from the temporomandibular joint (TMJ) and generate endogenous HA with high molecular weights. In a rat TMJ osteoarthritis inflammation model, this strategy promotes endogenous HA production and inhibits the synovial inflammation of OA for more than 3 weeks with one-shot administration. Such nanotherapy also helps repairing the bone defects in a rat OA bone defect model.
['Li|Huimin|H|', 'Guo|Huilin|H|', 'Lei|Chang|C|', 'Liu|Li|L|', 'Xu|Liqin|L|', 'Feng|Yaping|Y|', 'Ke|Jin|J|', 'Fang|Wei|W|', 'Song|Hao|H|', 'Xu|Chun|C|', 'Yu|Chengzhong|C|', 'Long|Xing|X|https://orcid.org/0000-0001-5794-1117']
D000818:Animals D002460:Cell Line D006801:Humans D000076002:Hyaluronan Synthases D006820:Hyaluronic Acid D042541:Intracellular Space D007596:Joints D008970:Molecular Weight D050997:Nanomedicine D053758:Nanoparticles D010003:Osteoarthritis D016062:Porosity D051381:Rats D012822:Silicon Dioxide D000070918:Synoviocytes
osteoarthritis hyaluronic acid nanoparticles drug carriers protein delivery